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Abstract  
BACKGROUND: Recent advances in multi-detector computed tomography (MDCT) 
facilitate acquiring important clinical information for managing patients with COPD. MDCT 
can detect the loss of lung tissue associated with emphysema as a low-attenuation area (LAA) 
and the thickness of airways as the wall area percentage (WA%). The percentage of small 
pulmonary vessels less than 5 mm
2
 (%CSA<5) has been recently recognized as a parameter for 
expressing pulmonary perfusion. We aimed to analyze the longitudinal changes in structural 
abnormalities using these CT parameters and analyze the effect of exacerbation and smoking 
cessation on structural changes in COPD patients. 
METHOD: We performed pulmonary function tests (PFTs), an MDCT and a COPD 
assessment test (CAT) in 58 patients with COPD at the time of their enrollment at the hospital 
and two years later. We analyzed the change in clinical parameters including CT indices and 
examined the effect of exacerbations and smoking cessation on the structural changes. 
RESULTS: The CAT score and FEV1 did not significantly change during the follow-up period. 
The parameters of emphysematous changes signiﬁcantly increased. On the other hand, the 
WA% at the distal airways significantly decreased or tended to decrease, and the %CSA<5 
slightly but significantly increased over the same period, especially in ex-smokers. The 
parameters of emphysematous change were greater in patients with exacerbations and continued 
to progress even after smoking cessation. In contrast, the WA% and %CSA<5 did not change in 
proportion to emphysema progression. 
CONCLUSION: The WA% at the distal bronchi and the %CSA<5 did not change in parallel 
with parameters of LAA over the same period. We propose that airway disease and vascular 
remodeling may be reversible to some extent by smoking cessation and appropriate treatment. 
Optimal management may have a greater effect on pulmonary vascularity and airway disease 
than parenchymal deconstruction in the early stage of COPD.  
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Background 
Chronic obstructive pulmonary disease (COPD) is the third leading cause of death globally 
and is associated with increasing economic costs and social burdens.
1
 Inflammation from 
cigarette smoking, the major cause of COPD, starts in the small airways and progresses to the 
lung parenchyma with alveolar destruction (lung emphysema) and then to the central airways, 
resulting in bronchiolitis (airway diseases).
2,3
 Pulmonary function tests (PFTs) are 
physiologically the gold standard for the diagnosis and staging of COPD. 
  Recent advances in multi-detector computed tomography (MDCT) facilitate the acquisition 
of important clinical information for managing patients with COPD. According to 
emphysematous changes, it can detect the loss of lung tissue associated with emphysema as a 
low-attenuation area (LAA). Mishima et al explored emphysema progression using an elastic 
spring network model and described that neighboring, small, low-attenuation clusters tend to 
coalesce and break under tension.
4
 In addition, a recent study analyzed the mean size of LAA 
clusters (LAS) and the number of low-attenuation clusters (LAN) by their sizes (small LAN, 
medium LAN, large LAN).
5,6
 Focusing on the airway disease, it was possible to analyze the 
inner luminal area and the wall thickness of airways at the level of the distal bronchi (from the 
third to the fifth or sixth bronchi) as inner luminal area (Ai) and wall area percentage (WA%), 
respectively.
7,8
 These indices were associated with airflow limitation, and such correlations were 
significant at the distal (small) rather than the proximal (large) airways. Moreover, airway wall 
percentage and airway wall thickness were greater in the subjects with chronic respiratory 
symptoms (cough, excessive mucous secretion, dyspnea, and wheezing) than those in the 
subjects without respiratory symptoms.
9
 They also associate with the clinical features that may 
represent chronic bronchitis, which has been reported to result in poor outcomes in COPD.
10,11
 
Finally, a new CT marker for expressing the area of small pulmonary vessels, the percentage of 
small pulmonary vessels (%CSA), has been introduced to reflect pulmonary vascular change 
and to correlate inversely with airflow limitation as well as with pulmonary hypertension and 
radiographic emphysema in COPD.
12,13
 We previously described that the percentage of small 
pulmonary vessels less than 5 mm
2
 (%CSA <5) was lower in COPD patients with the 
emphysema phenotype as compared with non-COPD smoker and COPD patients with the 
no/mild emphysema phenotype.
14
 
Although longitudinal studies about health status or lung function in COPD have been 
performed,
15
 the longitudinal changes in structural abnormalities in COPD have not been fully 
explored. Studies on emphysema progression have been addressed,
16-18
 but studies about the 
changes in airway disease
19
 or vascular remodeling are rare.
20
 The association between alveolar 
destruction, airway disease and pulmonary vascular change also remains unknown. Moreover, 
the data on structural changes after exacerbation or smoking cessation in COPD patients are not 
established. 
Therefore, the aims of this study were to explore the longitudinal change in structural 
abnormalities in COPD subjects using MDCT; to clarify the change in pulmonary emphysema, 
airway disease, and pulmonary vasculature; and to clarify the effect of an intervention such as 
smoking cessation and exacerbations on these structural abnormalities in COPD patients. 
 
Methods 
Subjects 
We enrolled 112 subjects who presented to Chiba University Hospital from May 2012 to July 
2014 for management of mild-to-very-severe COPD in a prospective, observational study 
investigating COPD exacerbations. COPD was diagnosed on the basis of past history, physical 
examination and spirometric data according to the American Thoracic Society (ATS) / European 
Respiratory Society (ERS) recommendations.
21
 Spirometric measurements were performed 
using a Fudac-60 (Fukuda Denshi; Tokyo, Japan). FVC and FEV1 were examined, and their 
predicted values were calculated according to the Japanese Respiratory Society (JRS) 
guidelines.
22
 
Twenty-five patients were excluded because of complications of asthma. We performed 
pulmonary function tests (PFTs), an MDCT and a COPD assessment test (CAT) in 87 patients 
with COPD at the time of their enrollment at the hospital and two years later. Ten patients were 
excluded because of abnormal chest shadows other than emphysematous changes: interstitial 
pneumonia (n=4), infectious pneumonia (n=1), old pulmonary tuberculosis (n=1), lung cancer 
or pulmonary nodule (n=4). Finally, 58 patients completed this study (Figure 1). We defined an 
exacerbation as the situation of deterioration of COPD that requires antibiotics and or systemic 
steroid use.
17
 
This study was approved by the ethics committee of the Chiba University School of Medicine 
(approval number: 857) and written informed consent was obtained from all study participants.  
MDCT scanning 
All patients underwent 64-MDCT scanning (Aquilion ONE, Toshiba Medical Systems; Tokyo, 
Japan) from the thoracic inlet to diaphragm while at full inspiration. No contrast medium was 
used. MDCT scan parameters were as follows: collimination of 0.5mm; 120kV; auto-exposure 
control; gantry rotation time of 0.5 seconds; and beam pitch of 0.83. All images were 
reconstructed using standard reconstruction algorithms with a slice thickness of 0.5 mm and a 
reconstruction interval of 0.5 mm. The voxel size was 0.63×0.63×0.5 mm. 
MDCT measurements 
We selected three CT slices for the measurements of LAA, LAN and CSA
12,14
: 
(a) The level at 1cm above the upper margin of the aortic arch (upper lung fields); (b) 1cm 
below the carina (middle lung fields); and (c) 1cm below the right inferior pulmonary vein 
(lower lung fields).   
Measurements of LAA, LAN, LAS and CSA were performed using a free open-source 
software, ImageJ Version 1.44 (imagej.nih.gov/ij/download/).
13,19
   
LAA measurements were performed according to the following steps. (1) The threshold 
technique for the total lung area was adopted with attenuation between -500 and -1024 HU.  
(2) These images were converted into binary images at a window level of -950 HU. (3) The 
range of circularity was set from 0 to infinity, and the LAA was summed using the "analyze 
particles" function of ImageJ software on each slice. We counted the number of LAA clusters 
(LAN) on each slice, and the LAN were divided into 3 categories by size of cluster (small LAN 
[sLAN], medium LAN [mLAN] and large LAN [lLAN]). The size of the clusters were as 
follows: small cluster, 0.4-8 mm
2
; medium, 8.4-40 mm
2
; and large, >40 mm
2
.
5
 LAAs on the 
three selected slices were summed, and the average of these values was determined. The LAS 
was obtained semi-automatically. 
The CSA measurements were performed according to the following steps.
12,14 
 (1) The 
threshold technique was adopted with attenuation between -500 and -1024 Hounsfield units 
(HU).  (2) These images were converted into binary images at a window level of -720 HU.  
(3) The range of circularity was set from 0.9 to 1.0 using the "analyze particles" function of 
ImageJ software.  (4) CSA was measured separately by the size of each vessel (less than 5 
mm
2
; CSA <5). CSAs on the three selected slices were summed, and the average of these values 
was determined. 
Measurements of WA% was performed using a free open-source software Airway Inspector 
(Brigham and Women’s Hospital).23 (1) We measured WA% according to the method of 
Yamashiro et al.
24
  (2) The WA% was measured semiautomatically with the full-width at a 
half-maximum method by the software. (3) We identified the third, fourth and fifth generations 
of airway bronchi (B1 and B10 in the right lung). We measured bronchi on the images that were 
peripheral and next to the branching point.  
These data were confirmed independently by two pulmonologists (ST and YM) who were 
blinded to all clinical information. 
 
Statistical analysis 
Data are expressed as mean (±SD). Comparisons between the quantitative measurements of the 
initial and follow-up CT scans, PFTs, and CAT scores were performed using the Wilcoxon 
signed-rank test. And comparisons of data between current smokers and ex-smokers were 
evaluated using the Mann-Whitney U test. Correlations of ΔLAA% with ΔLAN (ΔsLAN, 
ΔmLAN, ΔlLAN) were evaluated by Spearman’s rank correlation analysis. For all statistical 
analyses, the level of significance was set at p <0.05. All statistical analyses were performed 
using JMP 10.0 software (SAS Institute, Cary, NC). 
 
Results 
Patient characteristics 
Patient characteristics are presented in Table 1. There were 58 patients (51 men and 7 women; 
mean age 69.7 ± 7.3 years; mean FEV1/ FVC 55.9 ±12.0%). The number of patients with COPD 
in each Global Initiative for Chronic Obstructive Lung Disease (GOLD) stage were as follows: 
stage I, n = 14 (24.1%); stage II, n = 31 (53.4%); stage III, n = 9 (15.5%); stage IV, n = 4 (6.9%). 
The sum of GOLDI and II, defined as a mild-to-moderate form, was 77.5%. Forty-six patients 
(79.3%) were ex-smokers, and 12 patients (20.7%) were current-smokers. Fourteen patients had 
exacerbations, and the frequency of exacerbations per 2 years was 1.5±0.9 times. The number of 
patients who received COPD treatment was 21 (36%) at enrollment and 40 (69%) 2 years later. 
 
Change of CAT score and PFTs 
The CAT score and FEV1 did not significantly change during the follow-up period. FEV1/FVC 
(%) decreased slightly but significantly, and the V50/V25 slightly increased from the initial to 
the follow-up PFTs (Table 2). 
 
Change in CT parameters 
The CT parameters measured on the initial and follow-up CT scans are shown in Table 2. 
LAA, LAA%, LAN, sLAN and mLAN signiﬁcantly increased, and lLAN tended to increase 
from the initial to the follow-up CT scans. The changes in total lung area (TLA) or LAS were 
not significant. ΔLAA, ΔLAN and ΔsLAN, ΔmLAN, and ΔlLAN positively correlated with each 
other (Fig. 2). On the other hand, the WA% significantly decreased or tended to decrease at the 
distal airways (the fourth and fifth bronchi), and the CSA<5 and %CSA<5 slightly but 
significantly increased during the two years of follow-up. Interestingly, the WA% in the 
ex-smokers significantly decreased in the distal bronchi, and the %CSA<5 of ex-smokers 
slightly but significantly increased (Table 3). In contrast, neither the WA% or %CSA<5 in 
current smokers changed. In patients in the exacerbation group, the WA% and %CSA< 5 did not 
change during the follow-up period. In contrast, the WA% of patients without exacerbations 
significantly decreased, and %CSA significantly increased (Table 4) over the same period. The 
ΔLAN of the patients who had exacerbations significantly decreased in comparison with that of 
subjects without exacerbations (Figure 3). However, the change in the number of LAA grouped 
by size was not significantly different in patients with or without exacerbations (Table 5). 
 
 
  
Discussion 
The key findings in the present study were first, that the low-attenuation area and the number 
of clusters by size simultaneously increased during the follow-up period. The LAA clusters 
increased and coalesced from the initial to the follow-up CT scan. On the other hand, the 
percentage of the small pulmonary vessels and the bronchial wall thickness did not change in 
parallel with the parameters of emphysema progression. We found a difference in changes 
between three structural abnormalities in COPD. Second, the changes in the CT parameters of 
emphysema were greater in patients with exacerbations than in patients without exacerbations. 
Moreover, they also progressed even after smoking cessation. In contrast, the parameters of 
airway disease and pulmonary vasculature did not change in proportion to emphysema 
progression with exacerbations or smoking cessation. These findings suggest that the 
progression of emphysema and the change in pulmonary vasculature and airway disease do not 
always occur with each other after intervention or treatment for COPD. 
 
Although the CAT score and FEV1 did not significantly decrease, both the LAA and LAN 
increased during the follow-up period consistent with previous imaging studies.
5,16
 
Parenchymal destruction extended during the two years, and the number of clusters in each 
size also increased as emphysema extended. The changes of LAA% and the changes of LAN 
(including small, medium, and large LAN) were positively correlated in the present study. 
Parenchymal inflammation, mechanical forces and coalescence of the neighboring LAA 
clusters and others are considered as the mechanism that make the size of LAA clusters 
larger.
25-27
 Mishima et al modeled emphysema progression using an elastic spring network 
model and described that neighboring, small, low-attenuation clusters tend to coalesce and 
break under tension.
4
 They suggested the concept of the D exponent. The cumulative 
frequency distribution of LAA sizes, Y, could be described by a power law of LAA size X of 
the form: Y = K × X
-D
. The D value reflects the fractal dimension of the terminal airspace 
geometry and sensitively detects alveolar structural changes that were not reflected by the 
changes in LAA%. They analyzed longitudinal emphysema progression with the original 
simulation model in the subsequent studies.
17
 Another cross-sectional study described that the 
degree of coalescence of the clusters and the extent of emphysema depends on the size of 
clusters in the subjects with severe emphysema.
6
 They concluded that the coalescence of LAA 
requires the medium or large LAN, not the small LAN. Because our data are from a 
longitudinal study, we did not refer to the difference between our results and the previous study. 
But we speculate that coalescence and the new generation of clusters may happen 
simultaneously regardless of the size of clusters in mild-to-moderate COPD or mild 
emphysema. Seventy-five percent of our subjects belong to the mild-to-moderate stage, and 
emphysematous changes were mild as compared to those of previous studies.   
The changes in the emphysema area was greater in patients with exacerbations of COPD 
than in those without exacerbations, consistent with previous studies.
17,25
 LAN increased in 
both of the groups, but the change of LAN was greater in patients without exacerbations than 
in those with exacerbations (Table 5). However, the changes in small, medium, or large LANs 
were not different between the two groups. It may also suggest that exacerbations have an 
impact on the progression of emphysema and that coalescence and new formation of LAA 
might simultaneously happen.  
In addition, the LAA% increased in both the current and past smokers, consistent with a 
previous analysis.
16
 A more rapid decline in lung function was reported in participants with 
emphysema than in those without emphysema.
28
 Once lung inflammation and parenchyma 
destruction has been established by smoking,
21,29
 the emphysema progression might extend to 
some extent regardless of smoking cessation. 
 
Some cross-sectional studies reported that the %CSA<5 decreased with emphysematous 
change or airflow limitation.
13,14,30 
In addition, the %CSA<5 significantly correlated with 
pulmonary perfusion and reflected microvascular remodeling in the lung.
31
 A recent advanced 
study using gadolinium-enhanced MRI showed reductions in the pulmonary microvascular 
blood flow in the lung without clear evidence of emphysema, suggesting the presence of distinct 
pathological processes associated with emphysema change and pulmonary vascular remodeling 
in COPD.
32
 In the present study, the mean WA% at the distal bronchi slightly decreased, and 
the %CSA<5 slightly but significantly increased during the follow-up period, despite 
emphysema progression. The airway caliber change in proportion to the improvement in airflow 
limitation by inhaled anticholinergic agents has been shown in COPD patients.
18,33
 Saruya et al 
reported that there was a progressive increase in the extent of emphysema over time, but no 
signiﬁcant decrease in small pulmonary vessels over the same time period.20 They described that 
a decrease in the %CSA<5 may be associated with various improvements in the condition of the 
patients, such as smoking cessation, exacerbation risk, and pharmacotherapies, in comparison 
with emphysematous progression. Very recently, the morphological changes in small pulmonary 
vessels were reported to be associated independently with severe acute exacerbations.
34
 These 
findings support our results. 
In the present study, the %CSA<5 and the WA% at the distal bronchi in ex-smokers did not 
change in parallel with the progression of emphysema. Smoking cessation might decrease the 
inflammation of the bronchus, which led to a decrease of the WA% of the bronchi. In the 
ex-smokers group, the WA% decreased or tended to decrease in the distal bronchi, and 
the %CSA<5 significantly increased. In contrast, the WA% and %CSA<5 in current smokers 
did not significantly change. This may suggest that smoking cessation not only influences 
airway inflammation but also improves the pulmonary vasculature. 
 
Quality of life is related to exacerbation frequency,
35,36
 and mortality increases with the 
frequency of severe exacerbations in COPD.
37
 Exacerbations also occur in mild COPD, 
although at a lower frequency compared with moderate-to-severe disease,
38,39
 and exacerbations 
are involved in emphysema progression.
17,25
 In the present study, some patients with 
mild-to-moderate airflow limitation underwent exacerbations. Exacerbations cause 
inflammation of the airway, but smoking cessation and inhaled pharmacotherapies, such as 
beta-agonists, anticholinergics and steroids, reduce inflammation of the airways and the risk of 
exacerbations of COPD.
40-44
 In our study, the WA% and the % CSA<5 slightly changed in 
patients without exacerbations. We suppose that the WA% may be improved because of 
decreasing inflammation of the small airways due to the intervention, such as smoking cessation 
and appropriate treatment, which will lead to no exacerbations. Then, inflammation of the blood 
vessel accompanying the bronchial wall may be improved, and the %CSA<5 may be improved. 
The changes in the morphology of the small pulmonary vessels in COPD follow airway 
remodeling, and the complications of both airway and vascular change are associated with each 
other.
45
  
 
Interestingly, we previously reported that the WA% at the distal bronchi and the %CSA<5 
simultaneously decreased after 3 months of inhaled therapy in asthma-COPD overlap syndrome 
(ACOS) subjects.
46
 In the present study, the %CSA in subjects with smoking cessation and in 
subjects without exacerbations increased in accordance with the decrease of the WA% in 
COPD-alone subjects. We could not clarify the point in this study, but we speculate that it may 
be caused by the difference of the pathogenesis and responsiveness to intervention between 
COPD and asthma.
47,48
 In COPD, there is a well-known hypothesis that depleting vascular 
endothelial growth factor induces the apoptosis of parenchymal epithelial and endothelial cells 
and results in emphysematous changes.
49,50
 On the contrary, airway inflammation in asthma is 
accompanied by vascular endothelial growth factor and an increase in subepithelial 
microvessels.
48
 Based on these situations, the responsiveness to intervention will differ between 
the COPD-alone and ACOS subjects. In ACOS subjects, pharmacotherapies could improve the 
remodeling of both the airways and pulmonary vasculature by suppressing inflammation and 
leakage from immature microvessels, in addition to decreasing the local vascular constriction. 
We are conducting the next study to clarify the difference in structural changes between 
COPD-alone and ACOS subjects. 
 
The frequency of exacerbations also contributes to the long-term decline in lung function.
51
 
We conclude that there is a possibility that airway remodeling and small pulmonary vascular 
remodeling may react to interventions, such as smoking cessation and appropriate treatment, in 
particular in mild-to-moderate COPD patients. An aggressive smoking intervention program 
significantly reduces the age-related decline in FEV1.
52
 Further research focusing on the effects 
of early intervention (smoking cession, inhaled therapy and more) in mild-to-moderate COPD 
patients will be needed.
53
  
 
There were several limitations of our study. First, our sample size was relatively small, and most 
of the patients were male. We could not analyze the gender differences for longitudinal changes. 
A recent study mentioned the association of male gender with clinical features of chronic 
bronchitis in COPD.
 11 
Second, the observational period of 2 years was not long.
17
 Although this 
study was conducted at a single institute, our data were accurate and reproducible because all 
the parameters were assessed using the same equipment during the follow-up period. Third, we 
could not evaluate the effect of the pharmacotherapies on CT parameters because of our sample 
size and the short follow-up period. However, a large cohort study showed that inhaled therapy 
could decrease the exacerbation risk and reduce the decline of pulmonary function during 4 
years of follow-up.
 40,54
 We would like to elucidate these points in a follow-up study. Finally, 
78.5% of patients were in the mild-to-moderate stage of COPD in this study; therefore, it may 
turn out differently with the reports focusing on patients in stages that are severe to very severe. 
We could not analyze the subjects according to the disease severity because of our sample size. 
However, there are few reports focusing on a relatively early stage of COPD; therefore, this 
study is useful for managing COPD patients in clinical practice. 
 
Conclusion 
In conclusion, the WA% at the distal bronchi and the %CSA <5 did not change in parallel 
with emphysema progression during the follow-up period. By using WA% and %CSA <5, we 
could evaluate the change in airway remodeling and pulmonary vasculature in addition to 
emphysematous progression. Optimal management may have an effect on the pulmonary 
vasculature and airway disease in the early stage of COPD. 
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 Figure 1. Patient disposition and reason for exclusion. 
CT = computed tomography; COPD = chronic obstructive pulmonary disease; PFTs = 
pulmonary function tests. 
 
  
 
 
 
 
 
 
 
 
 
 
 Figure 2. Correlations between ΔLAA% and ΔLAN, ΔsLAN, ΔmLAN, and ΔlLAN. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 3. The change in LAN in the patients with/without exacerbations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 1. Characteristics of study participants with COPD  
 
 
SD, standard deviation; BMI, body mass index;  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Mean (±SD) 
Age (years) 69.7 ± 7.3 
Sex (male/female) 51 (87.9%) / 7 (12.1%) 
Ex-smokers/Current smokers 46 (79.3%) / 12 (20.7%) 
Smoking history (pack-years) 54.9 ± 36.6 
BMI (kg/m
2
) 23.5 ± 2.9 
GOLD classification 
(Ⅰ/Ⅱ/Ⅲ/Ⅳ) 
14 (24.1%) / 31 (53.4%) / 
9 (15.5%) / 4 (6.9%) 
Exacerbations (+/-) 14 (24.1%) / 44 (75.9%) 
Exacerbations per 2 years 1.5 ± 0.9 
COPD Treatment (Yes/No) at enrollment 21 (36.2%) / 37 (63.8%) 
COPD Treatment (Yes/No) after 2 years 40 (69.0%) / 18(31.0%) 
Table 2. Longitudinal changes in CAT score, PFTs, and CT measurements in the follow-up 
period 
 
 
Variables Baseline 
Mean (±SD) 
2-Year Follow-up 
Mean (±SD) 
P value 
CAT score 9.1 ± 6.8 8.4 ± 7.1 NS 
FVC (L) 3.12 ± 0.71 3.17 ± 0.80 NS 
FEV1 (L) 1.75 ± 0.59 1.75 ± 0.61 NS 
FEV1/FVC (%) 55.9 ± 12.0 54.67 ± 11.9 p=0.045 
FEV1% predicted (%) 65.3 ± 19.81 67.3 ± 21.1 NS 
V50/V25 3.6 ± 1.2 4.0 ± 1.6 p=0.046 
TLA (mm
2
) 22421 ± 3372 22164 ± 3502 NS 
LAA (mm
2
) 1782 ± 2778 2254 ± 3093 P<0.001 
LAA% (%) 7.2 ± 1.4 9.2 ± 11.7 P<0.001 
CSA<5 (mm
2
) 156.5 ± 33.0 167.6 ± 38.9 p=0.011 
%CSA<5 (%) 0.71 ± 0.19 0.77 ± 0.21 p=0.006 
LAN 181.5 ± 132.5 260.3 ± 148.1 P<0.001 
LAS (mm
2
) 8.04 ± 12.4 8.27 ± 12.4 NS 
sLAN 138.6 ± 93.4 207.5 ± 117.2 P<0.001 
mLAN 19.5 ± 24.1 23.0 ± 26.6 p=0.021 
lLAN 4.8 ± 7.6 5.7 ± 8.2 NS 
B1 WA%    
third 72.9 ± 6.9 72.2 ± 6.1 NS 
Fourth 79.6 ± 7.5 77.3 ± 6.7 P=0.018 
Fifth 84.4 ± 4.7 83.1 ± 4.6 P=0.050 
B10 WA%    
Third 71.0 ± 6.7 69.3 ± 6.5 NS 
Fourth 78.9 ± 6.2 77.6 ± 6.6 P=0.092 
Fifth 83.8 ± 3.8 80.9 ± 5.9 P<0.001 
Mean WA%    
Third 72.0 ± 5.8 70.9 ± 4.5 NS 
Fourth 79.2 ± 5.3 77.4 ± 5.2 P=0.016 
Fifth 84.0 ± 3.4 82.0 ± 4.3 P=0.001 
CAT score, COPD assessment test score; FVC, forced vital capacity; FEV1, forced expiratory 
volume in 1 second; TLA, total lung area; LAA, low-attenuation area; LAN, the number of 
low-attenuation clusters; LAS, the mean size of low-attenuation clusters; CSA<5, the 
cross-sectional area of pulmonary vessels < 5 mm
2
; WA%, wall area percentage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3. Longitudinal changes of WA%, %CSA<5, and LAA% in the patients with current 
smoking, and smoking cessation   
 
LAA, low-attenuation area; CSA<5, the cross-sectional area of pulmonary vessels <5 mm
2
; 
WA%, wall area percentage: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Baseline 
Mean(±SD) 
Follow-up 
Mean(±SD) 
P value 
Current smokers 
WA% third 72.7 ± 7.1 72.8 ± 5.9 NS 
Fourth 79.8 ± 6.5 78.5 ± 4.1 NS 
Fifth 83.3 ± 4.6 82.2 ± 4.3 NS 
%CSA<5 0.73 ± 0.18 0.72 ± 0.21 NS 
LAA% 5.7 ± 8.8 8.9 ± 12.0 P=0.001 
Ex-smokers 
WA% third 71.8 ± 5.5 70.4 ± 4.0 P=0.092 
Fourth 79.0 ± 5.0 77.1 ± 5.4 P=0.016 
Fifth 84.2 ± 3.0 81.9 ± 4.4 P<0.001 
%CSA<5 0.71 ± 0.19 0.78 ± 0.21 P<0.001 
LAA% 7.6 ± 11.0 9.3 ± 12.0 P<0.001 
Table 4. Longitudinal changes of WA%, %CSA<5, and LAA% in the patients with/ without 
exacerbations   
 
 
LAA, low-attenuation area; CSA<5, the cross-sectional area of pulmonary vessels <5 mm
2
; 
WA%, wall area percentage 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Variables Baseline 
Mean(±SD) 
Follow-up 
Mean(±SD) 
P value 
Exacerbations (+) 
WA% third 71.7 ± 6.2 72.3 ± 5.2 NS 
Fourth 78.9 ± 5.9 78.7 ± 5.1 NS 
Fifth 84.6 ± 3.4 83.3 ± 3.8 NS 
%CSA<5 0.73 ± 0.22 0.74 ± 0.20 NS 
LAA% 10.1 ± 13.9 12.4 ± 15.0 P=0.029 
Exacerbations (-) 
WA% third 72.1 ± 5.8 70.4 ± 4.3 P=0.027 
Fourth 79.2 ± 5.2 77.0 ± 5.2 P=0.012 
Fifth 83.9 ± 3.4 81.5 ± 4.4 P=0.002 
%CSA<5 0.71 ± 0.18 0.78 ± 0.21 P=0.004 
LAA% 6.3 ± 9.1 8.2 ± 10.5 P<0.0001 
Table 5. Longitudinal changes of ΔLAN and Δs,m.l LAN in the patients with/without 
exacerbations 
 
LAN, the number of low-attenuation clusters: 
sLAN, small LAN; mLAN, medium LAN; lLAN, large LAN  
The size of the clusters: small, 0.4-8 mm
2
; medium, 8.4-40 mm
2
; and large >40 mm
2
. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Exacerbations (-) Exacerbations (+) P value 
ΔLAN 94.1 ± 95.5 30.7 ± 103.8 P=0.032 
ΔsLAN 80.8 ± 90.5 31.5 ± 85.3 NS 
ΔmLAN 3.3 ± 14.8 4.2 ± 13.6 NS 
ΔlLAN 0.9 ± 3.7 1.0 ± 4.2 NS 
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